Palbociclib is a CDK4/6 inhibitor effective in preclinical breast cancer models.95 After identifying cyclin-dependent kinases as essential regulators of cell proliferation, Pfizer Inc. developed palbociclib. This evidence concerns the gene CDK4 and breast carcinoma.